- Hong Kong
- /
- Food and Staples Retail
- /
- SEHK:314
Sipai Health Technology Full Year 2024 Earnings: CN¥0.51 loss per share (vs CN¥0.40 loss in FY 2023)
Sipai Health Technology (HKG:314) Full Year 2024 Results
Key Financial Results
- Revenue: CN¥4.57b (down 3.1% from FY 2023).
- Net loss: CN¥323.7m (loss widened by 27% from FY 2023).
- CN¥0.51 loss per share (further deteriorated from CN¥0.40 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Sipai Health Technology shares are up 21% from a week ago.
Balance Sheet Analysis
Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of Sipai Health Technology's balance sheet and an in-depth analysis of the company's financial position.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SEHK:314
Sipai Health Technology
Operates as a medical technology and health management company in the People’s Republic of China.
Flawless balance sheet and overvalued.